EMA Authorised: Kisqali (ribociclib succinate) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Kisqali (ribociclib succinate) for breast cancer in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Novartis Europharm Limited. Decision date: 23/01/2026